Shilpa Medicare and Subsidiary Biocare Form Strategic Equity Partnership with Gate2Brain to Advance Brain Cancer Therapy

Shilpa Medicare and Subsidiary Biocare Form Strategic Equity Partnership with Gate2Brain to Advance Brain Cancer Therapy​

Shilpa Biocare Pvt Ltd, a wholly-owned subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED), has entered into a strategic equity partnership with Gate2Brain, S.L., a Barcelona-based biotechnology company. This move positions Shilpa as a key strategic shareholder and an integrated Contract Manufacturing and Development Organization (CDMO) and regulatory partner for G2B-002, Gate2Brain's lead candidate for brain cancer.

The transaction involves the acquisition of a 30.4% equity stake in Gate2Brain. The total contribution for this equity stake amounts to Euro 7 million. The consideration details include a cash infusion of Euro 0.5 million, Equity for services of Euro 5.5 million, and an additional Euro 1 million dedicated to project development.

Gate2Brain is focused on developing peptide-based delivery systems that transport therapeutics across the blood-brain barrier (BBB) for central nervous system (CNS) diseases. G2B-002 utilizes a proprietary MiniAp4 peptide shuttle to deliver SN-38, a potent anticancer agent, across the BBB.

G2B-002 has secured Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The drug candidate is designed to target Diffuse Intrinsic Pontine Glioma (DIPG) and pediatric glioblastoma (pGBM), which are highly lethal brain cancers, particularly in children.

In preclinical studies, the MiniAp4 peptide shuttle demonstrated up to 100-fold greater brain drug transport compared to conventional methods in animal models. The platform's activity has also been shown across other rare pediatric cancers, including Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma. Clinical batches for G2B-002 are anticipated as early as next year, with first-in-human trials expected by FY28.

The partnership reinforces Shilpa's strategy of investing in high-potential therapeutic innovation. Management from both companies highlighted the significance of this collaboration. Vishnukant Bhutada, Managing Director of Shilpa Medicare Ltd., stated that Gate2Brain’s technology is one of the most differentiated CNS-delivery platforms they have reviewed.

Meritxell Teixidó Turà, CEO of Gate2Brain, noted that the partnership provides G2B-002 a clear path to the clinic and validates their peptide-shuttle platform with Shilpa as a top-tier oncology partner.

Market Opportunity for Neuro-Oncology Therapeutics​

G2B-002 is positioned to address several significant and high-need oncology markets, according to third-party market data:


The broad applicability of Gate2Brain's MiniAp4 peptide-shuttle platform across rare pediatric cancers and potential expansion into other CNS therapeutic categories expands the long-term commercial prospects beyond brain tumors.

SHILPAMED Stock Price Movement​

As of 9:24 AM, shares of Shilpa Medicare Limited are slipping by 1.09% in live trading, currently priced at ₹511.7 following the day's decline of ₹5.65. The stock is moving within a volatile range this morning, as its intraday low reached as low as ₹509.8.